Kodiak Sciences Inc
KOD23.040USD
+2.030+9.66%
終値 02/06, 16:00（ET）15分遅れの株価
1.22B時価総額
損失額直近12ヶ月PER
詳細情報 Kodiak Sciences Inc 企業名
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Incの企業情報
企業コードKOD
会社名Kodiak Sciences Inc
上場日Oct 04, 2018
最高経営責任者「CEO」Perlroth (Victor)
従業員数109
証券種類Ordinary Share
決算期末Oct 04
本社所在地1250 Page Mill Rd
都市PALO ALTO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94304
電話番号16502810850
ウェブサイトhttps://kodiak.com/
企業コードKOD
上場日Oct 04, 2018
最高経営責任者「CEO」Perlroth (Victor)
Kodiak Sciences Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+1152.00%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+1152.00%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Feb 8
更新時刻: Sun, Feb 8
株主統計
種類
株主統計
株主統計
比率
Baker Bros. Advisors LP
32.66%
Point72 Asset Management, L.P.
4.65%
Perlroth (Victor D)
4.42%
BlackRock Institutional Trust Company, N.A.
3.93%
The Vanguard Group, Inc.
3.79%
他の
50.55%
株主統計
株主統計
比率
Baker Bros. Advisors LP
32.66%
Point72 Asset Management, L.P.
4.65%
Perlroth (Victor D)
4.42%
BlackRock Institutional Trust Company, N.A.
3.93%
The Vanguard Group, Inc.
3.79%
他の
50.55%
種類
株主統計
比率
Hedge Fund
46.25%
Investment Advisor
19.99%
Investment Advisor/Hedge Fund
9.35%
Individual Investor
4.78%
Research Firm
1.78%
Endowment Fund
1.13%
Private Equity
1.04%
Pension Fund
0.17%
Sovereign Wealth Fund
0.08%
他の
15.43%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
262
48.78M
79.97%
+1.55M
2025Q3
248
41.93M
79.39%
-9.11M
2025Q2
273
46.04M
87.25%
-8.67M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Baker Bros. Advisors LP
19.92M
32.66%
+2.61M
+15.07%
Dec 18, 2025
Point72 Asset Management, L.P.
2.84M
4.65%
+2.38M
+526.72%
Sep 30, 2025
Perlroth (Victor D)
2.70M
4.42%
+527.00K
+24.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.40M
3.93%
-286.86K
-10.68%
Sep 30, 2025
The Vanguard Group, Inc.
1.95M
3.2%
+127.99K
+7.02%
Sep 30, 2025
Adage Capital Management, L.P.
1.33M
2.19%
-720.71K
-35.06%
Sep 30, 2025
ICONIQ Capital, LLC
1.27M
2.08%
--
--
Sep 30, 2025
TCG Crossover Management, LLC
1.15M
1.88%
--
--
Sep 30, 2025
SilverArc Capital Management, LLC
1.00M
1.64%
+598.46K
+149.04%
Sep 30, 2025
Acadian Asset Management LLC
969.91K
1.59%
-999.97K
-50.76%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Fidelity Enhanced Small Cap ETF
0.18%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
iShares Health Innovation Active ETF
0.06%
iShares Russell 2000 Value ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.05%
ProShares Hedge Replication ETF
0.03%
ProShares UltraPro Russell2000
0.03%
Proshares Ultra Russell 2000
0.02%
詳細を見る
Fidelity Enhanced Small Cap ETF
比率0.18%
iShares Micro-Cap ETF
比率0.11%
Vanguard US Momentum Factor ETF
比率0.11%
Invesco RAFI US 1500 Small-Mid ETF
比率0.06%
iShares Health Innovation Active ETF
比率0.06%
iShares Russell 2000 Value ETF
比率0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.05%
ProShares Hedge Replication ETF
比率0.03%
ProShares UltraPro Russell2000
比率0.03%
Proshares Ultra Russell 2000
比率0.02%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
